Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review

References

• Novel Coronavirus Pneumonia Emergency Responde Epidemiology Team. The epidemiological characteristics of an outbreak of2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):113–122.
   Google Scholar
• World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) situation report – 88. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200417-sitrep-88-covid-191b6cccd94f8b4f219377bff55719a6ed.pdf?sfvrsn=ebe78315_6. Accessed October 3, 2020.
   Google Scholar
• Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19.. Lancet Infect Dis. 2020;20:398–400.
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395:473–475. doi:10.1016/S0140-6736(20)30317-2
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:9. doi:10.1371/journal.pmed.0030343
   Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.01047
   PubMed Web of Science ®Google Scholar
• Chinese Clinical Trial Registry. Chinese Clinical Trial Registry. 2020. Available from: http://www.chictr.org.cn/. Accessed 2020 May 10
   Google Scholar
• Mcguire LW, Redden WR. Treatment of influenza pneumonia by the use of convalescent human serum: preliminary report. J Am Med Assoc. 1918;71(16):1311. doi:10.1001/jama.1918.26020420013013e
   Google Scholar
• Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004;24(1):44–46. doi:10.1007/s10096-004-1271-9
   Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA – J Am Med Assoc. 2020;323(29):1582–1589. doi:10.1001/jama.2020.4783
   Google Scholar
• Tan L, Kang X, Zhang B, et al. A special case of COVID-19 with long duration of viral shedding for 49 days. medRxiv. 2020. doi:10.1101/2020.03.22.20040071
   Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020;117(17):9490–9496. doi:10.1073/pnas.2004168117
   PubMed Web of Science ®Google Scholar
• Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. doi:10.3346/jkms.2020.35.e149
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection. Chest. 2020;S0012-3692(20):30571–30577.
   Google Scholar
• Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52:65S–79S. doi:10.1111/j.1537-2995.2012.03663.x
   PubMed Web of Science ®Google Scholar
• Eickmann M, Gravemann U, Handke W, et al. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion. 2018;58(9):2202–2207. doi:10.1111/trf.14652
   PubMed Web of Science ®Google Scholar
• Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72–73. doi:10.1016/j.micinf.2020.02.006
   PubMed Web of Science ®Google Scholar
• Xu Y, Xu Z, Liu X, et al. Clinical findings in critically ill patients infected with SARS-CoV-2 in Guangdong Province, China: a multi-center, retrospective, observational study. medRxiv. 2020 doi:10.1101/2020.03.03.20030668
   Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Coronavirus. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 2020 May 10
   Google Scholar
• Rothan HA, Byrareddy SN. The epidemeology and pathogenesis of coronavirus (Covid-19) outbreak. J Autoimmun. 2020;109:102433. doi:10.1016/j.jaut.2020.102433
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest. 2020;50(3):e13209. doi:10.1111/eci.13209
   PubMed Web of Science ®Google Scholar
• Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Heal. 2020;8(4):e488–96. doi:10.1016/S2214-109X(20)30074-7
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Novel Coronavirus (2019-nCoV) situation reports. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed 2020 Apr 11.
   Google Scholar
• Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev. 2020;S0887-7963(20):30025.
   Web of Science ®Google Scholar
• Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71. doi:10.5582/bst.2020.01020
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa2001191
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14. doi:10.1038/s41467-019-13940-6
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. NHC. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection. 2020. Available from: http://www.nhc.gov.cn/yzygj/. Accessed 2020 Apr 11.
   Google Scholar
• Multicenter, Pneumonia. collaboration group of D of S and T of GP and HC of GP for chloroquine in the treatment of novel coronavirus. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Chinese J Tuberc Respir Dis. 2020;43(3):185–188. Chinese.
   Google Scholar
• Gautret P, Lagier J-C, Parola P, Hoang VT, Al E. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663. doi:10.1016/j.tmaid.2020.101663
   PubMed Web of Science ®Google Scholar
• Zhao JP, Hu Y, Du RH, et al. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. Chinese J Tuberc Respir Dis J Tuberc Respir Dis. 2020;43(3):183–184. Chinese.
   Google Scholar
• Horby PW, Lim W; Recovery Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020.
   Web of Science ®Google Scholar
• Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? In: Annals of Internal Medicine. Vol. 145. American College of Physicians; 2006: 599–609. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16940336. Accessed October 3, 2020.
   Google Scholar
• Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–922. doi:10.1093/jac/dki346
   PubMed Web of Science ®Google Scholar
• Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003;9(3):199–201.
   Google Scholar
• Kong L. Severe acute respiratory syndrome (SARS). Transfus Apher Sci. 2003;29(1):101. doi:10.1016/S1473-0502(03)00109-5
   Google Scholar
• Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617–622. doi:10.3851/IMP3243
   PubMed Web of Science ®Google Scholar
• U.S.Food & Drug. Investigational COVID-19 Convalescent Plasma- Emergency INDs. 2020. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed 2020 May 11.
   Google Scholar
• Chun S, Chung CR, Ha YE, et al. Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome. Ann Lab Med. 2016;36(4):393–395. doi:10.3343/alm.2016.36.4.393
   Web of Science ®Google Scholar
• Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24(1):91.
   PubMed Web of Science ®Google Scholar
• Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890–1901. doi:10.1002/jmv.25882
   PubMed Web of Science ®Google Scholar
• Li L, Li L, Zhang W, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA – J Am Med Assoc. 2020;324(5):460. doi:10.1001/jama.2020.10044
   PubMed Web of Science ®Google Scholar
• Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59(3):102790. doi:10.1016/j.transci.2020.102790
   Web of Science ®Google Scholar
• Liu S, Liu X, Zhao S, et al. An exceptional peroxide birefringent material resulting from d–π interactions. Angew Chemie – Int Ed. 2020;59(24):9414–9417. doi:10.1002/anie.202002828
   Web of Science ®Google Scholar
• Okba NMA, Widjaja I, Li W, et al. Serologic detection of Middle East respiratory syndrome coronavirus functional antibodies. Emerg Infect Dis. 2020;26(5):1024–1027. doi:10.3201/eid2605.190921
   PubMed Web of Science ®Google Scholar
• U.S.Food & Drug. Recommendations for Investigational COVID-19 Convalescent Plasma. 2020. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed 2020 May 12.
   Google Scholar
• Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. SSRN Electron J. 2020.
   Google Scholar
• Ferreira LMR, Mostajo-Radji MA. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic. Npj Vaccines. 2020;5:58. doi:10.1038/s41541-020-0209-2
   Google Scholar
• McLaughlin K. China’s AIDS history explains part of the “CRISPR babies” story. STAT. 2020. Available from: https://www.statnews.com/2018/12/14/china-aids-history-crispr-babies/. Accessed 2020 Aug 22.
   Google Scholar
• Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 2016;352(6288):1001–1004. doi:10.1126/science.aaf1279
   PubMed Web of Science ®Google Scholar
• Pawar AY, Hiray AP, Sonawane DD, Bhambar RS, Derle DV, Ahire YS. Convalescent plasma: a possible treatment protocol for COVID-19 patients suffering from diabetes or underlying liver diseases. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):665–669. doi:10.1016/j.dsx.2020.05.023
   Web of Science ®Google Scholar
• Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med. 2015;3(7):554–562. doi:10.1016/S2213-2600(15)00180-0
   PubMed Web of Science ®Google Scholar
• Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol. 2009;147(4):431–443.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014;2:6.
   Google Scholar
• Wang SF, Tseng SP, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208–214. doi:10.1016/j.bbrc.2014.07.090
   PubMed Web of Science ®Google Scholar
• Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly. 2020;150:1516.
   Web of Science ®Google Scholar